Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice

Experimental Neurology
Hidefumi ItoHirofumi Kusaka

Abstract

Edaravone is a free-radical scavenger, an agent being widely used for cerebral ischemia in Japan. To evaluate its efficacy for possible treatment of amyotrophic lateral sclerosis (ALS), we performed a randomized blind trial in ALS model mice. After identification of the clinical onset in each female G93A mutant SOD1 transgenic mouse, we intraperitoneally administered multiple doses of edaravone to the mice and observed their motor symptoms. We also counted the number of lumbar motoneurons, determined the 3-nitrotyrosine/tyrosine ratio, and evaluated the abnormal SOD1 aggregation in the spinal cord at the 10th day after the edaravone injection. Edaravone significantly slowed the motor decline of the transgenic mice. The remaining motoneurons were significantly preserved in the higher-dose edaravone-administered group, and the 3-nitrotyrosine/tyrosine ratios were reduced dose-dependently. Intriguingly, the area of abnormal SOD1 deposition in the spinal cord was significantly decreased in the higher-dose edaravone-administered group. Our results indicate that edaravone was effective to slow symptom progression and motor neuron degeneration in the ALS model mice. These favorable actions might be attributable to the yet unidentified...Continue Reading

References

Sep 1, 1989·Stroke; a Journal of Cerebral Circulation·H NishiA Ishibashi
Aug 12, 1993·Nature·J S BeckmanW H Koppenol
Oct 22, 2002·Expert Opinion on Investigational Drugs·Mandy JacksonJeffrey D Rothstein
Mar 28, 2003·Biochemical and Biophysical Research Communications·Shinsuke TobisawaTakeo Kato
Jun 5, 2004·The Journal of Pharmacology and Experimental Therapeutics·Xin QiYasuyuki Nomura
Jun 19, 2004·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Chandrasekaran RamanMary E Abood
Jun 26, 2004·Annual Review of Neuroscience·Lucie I BruijnDon W Cleveland
Jul 19, 2005·Journal of the Neurological Sciences·T D Heiman-PattersonG M Alexander
Jul 29, 2005·Annals of Neurology·John P CrowM Flint Beal
Aug 16, 2006·Journal of Zhejiang University. Science. B·Ying SongEr-qing Wei
Oct 4, 2006·Neuron·Séverine BoilléeDon W Cleveland
Nov 28, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Hiide Yoshino, Akio Kimura
Feb 16, 2007·Neurobiology of Disease·Michael Benatar

❮ Previous
Next ❯

Citations

Jun 28, 2011·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Peter I JoyceAbraham Acevedo-Arozena
May 10, 2013·Journal of Molecular Neuroscience : MN·Bing LiZhiying Xu
Jun 21, 2011·PloS One·Jesse A SolomonMazen J Hamadeh
Dec 8, 2009·Neuropsychiatric Disease and Treatment·Stefano ZoccolellaPaolo Lamberti
Oct 8, 2014·Journal of Neurosciences in Rural Practice·Aicha Slassi SennouOuafae Messouak
Aug 30, 2014·The International Journal of Neuroscience·Yanxin RenYuyang Zhang
Aug 3, 2011·Expert Opinion on Emerging Drugs·Ali Aamer Habib, Hiroshi Mitsumoto
Oct 7, 2014·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Koji AbeUNKNOWN Edaravone ALS Study Group
Nov 1, 2013·Drug Discovery Today·Bariş Genç, P Hande Özdinler
Dec 9, 2009·Free Radical Biology & Medicine·Siân C Barber, Pamela J Shaw
May 8, 2009·Revue neurologique·P-F PradatUNKNOWN coordination des centres de prise en charge des patients atteints de SLA
Mar 17, 2009·Experimental Neurology·Ryosuke Takahashi
Nov 26, 2015·Irish Journal of Medical Science·J Zheng, X Chen
Oct 27, 2011·Biochemical and Biophysical Research Communications·Takao ShinozawaDaishi Watabe
Sep 2, 2014·Brain Research·Michael JablonskiDavide Trotti
May 8, 2014·BioMed Research International·Feng HeJun Liu
Jul 23, 2015·Molecular Neurobiology·Ewa NiedzielskaMałgorzata Filip
May 29, 2013·Journal of the Neurological Sciences·Shailendra Kapoor
Jul 4, 2016·European Journal of Medicinal Chemistry·Vijay KumarFaizan Ahmad
Jun 30, 2016·Expert Opinion on Pharmacotherapy·H BlascoP H Gordon
Jul 9, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·William DeCoteauJoseph S Erlichman
Jun 19, 2013·Thérapie·Lucie AyachPatrice Vanelle
Aug 2, 2008·Proceedings of the National Academy of Sciences of the United States of America·Clemens R ScherzerMichael G Schlossmacher
Mar 10, 2017·Expert Opinion on Investigational Drugs·Ana MartinezCarmen Gil
Apr 14, 2017·Expert Opinion on Pharmacotherapy·Hideyuki Sawada
Sep 5, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Carmel Armon
Dec 10, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Marion C HoggJochen H M Prehn
Mar 3, 2018·Journal of Neuroinflammation·Antonio VallarolaCaterina Bendotti
Sep 6, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Nicholas J Maragakis
Jul 19, 2013·Cellular and Molecular Life Sciences : CMLS·Rachna S PandyaXin Wang
Jan 18, 2018·EMBO Molecular Medicine·Amit U JoshiDaria Mochly-Rosen
Dec 23, 2017·Frontiers in Molecular Neuroscience·Andrew P Tosolini, James N Sleigh
Nov 30, 2019·Muscle & Nerve·B Jane Distad, Michael D Weiss
Jan 9, 2020·The International Journal of Neuroscience·Maria Bandookwala, Pinaki Sengupta

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.